Pfizer asks docs to sign ‘Dear Insurer’ letters

Share this article:
Pfizer is enlisting doctors in its efforts to stave off generic erosion of Lipitor. The company has supplied doctors with a CD containing letters they can send to pharmacists and insurers petitioning them not to switch patients from Lipitor to a generic statin, according to USA Today. Public Citizen’s Sidney Wolf told the paper that the company was using doctors as “human shields” to protect its business. “I would say it’s unethical,” said Wolf. Merck’s Zocor (simvastatin) went off-patent last June. Lipitor, which loses exclusivity in 2010, is also struggling to preserve its market share against branded competitors Vytorin, from Merck/Schering-Plough, and Crestor, from AstraZeneca. Pfizer scored a Lipitor patent victory yesterday when The Supreme Court declined to intervene in Ranbaxy Laboratories appeal of a lower-court ruling upholding a Pfizer patent for Lipitor. Indian generics firm Ranbaxy was seeking to sell a generic version of Lipitor. The court's decision not to get involved appears to settle the matter in Pfizer's favor.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.